Key result
Combined cardiometabolic and OSA therapy improves LV mass index by ~44% in a case report.
Why the study?
The relationship between arterial stiffness measured by cardio-ankle vascular index (CAVI) and left ventricular concentric hypertrophy during treatment was not previously demonstrated.
Case Report (n=1)
No
Hypothesis-generating for combined cardiometabolic and sleep apnea management; randomized trials needed to confirm outcomes.
A 42-year-old hypertensive woman came to our hospital suffering from shortness of breath. Her left ventricular mass index (LVMI) was increased, and a new arterial stiffness index, cardio-ankle vascular index (CAVI), was also elevated. By treating hypertension (HT), diabetes mellitus (DM) and obstructive sleep apnea (OSA), her left ventricular concentric hypertrophy was improved, accompanying with a decrease in CAVI. These observations suggested that arterial stiffness monitored with CAVI might be involved in cardiac hypertrophy. This cardio-vascular interaction could be demonstrated at the first time by monitoring CAVI, which is not affected by blood pressure (BP) at measuring time.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2019) conducted a case report in Hypertension, Left Ventricular Concentric Hypertrophy, Diabetes Mellitus, Obstructive Sleep Apnea (n=1). Combined treatment (antihypertensives including spironolactone, continuous positive airway pressure, and antidiabetic agents) vs. Baseline (untreated state) was evaluated on Changes in left ventricular mass index (LVMI), global longitudinal strain (GLS), and cardio-ankle vascular index (CAVI). Combined treatment of hypertension, diabetes, and sleep apnea improved left ventricular mass index from 128 to 72 g/m2 alongside a reduction in cardio-ankle vascular index from 9.1 to 7.2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: